Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 31Pemetrexed 28Radiotherapy 22Bevacizumab 21Cisplatin 20Gemcitabine 18Paclitaxel 17Erlotinib Hydrochloride 15Docetaxel 12Gefitinib 8Nivolumab 6Mastectomy, Segmental 6Magnetic Resonance Spectroscopy 6pembrolizumab 5aflutinib 5Radiosurgery 5tislelizumab 4Vinorelbine 4Surgical Procedures, Operative 4Specimen Handling 4Sorafenib 4Platinum 4Metformin 4Biopsy 42-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 4sargramostim 3apatinib 3Taxes 3Cetuximab 3Anterior Temporal Lobectomy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma of Lung × Genetic Linkage × Clear all
NCT01557959 2018-06-29

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Wake Forest University Health Sciences

Phase 2 Completed
45 enrolled 9 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡